-
公开(公告)号：US20150353248A1
公开(公告)日：2015-12-10
申请号：US14300346
申请日：2014-06-10
申请人： Derrell Craig McPherson , Christopher L. Hooban , Robert Michael Kinter , Dena H. Kota , Zachary A. Minter
发明人： Derrell Craig McPherson , Christopher L. Hooban , Robert Michael Kinter , Dena H. Kota , Zachary A. Minter
CPC分类号： B65D51/241 , F26B5/06
摘要： A lid assembly is provided for covering and sealing a lyophilizer tray that contains a material for freeze-drying into a product in a lyophilizer chamber. The tray has an opening defined by a peripheral lip. The lid assembly includes a first lid disposable to seal around the lip of the tray, second lid disposed on the first lid, and a filter paper disposed therebetween. The first lid includes an opening. The second lid covers the opening and includes a hole over the opening. The filter paper is disposed over the opening between the first and second lids for inhibiting the product from escaping the tray through the hole while permitting water vapor to pass therethrough. With a lyophilization stopper to seal the hole, the tray containing the product can be protected from environmental humidity even after removal from the chamber.
摘要翻译： 提供盖组件，用于将包含用于冷冻干燥的材料的冻干盘覆盖并密封在冻干室中的产品中。 托盘具有由外围唇缘限定的开口。 盖组件包括一次性用于围绕托盘的唇缘密封的第一盖，设置在第一盖上的第二盖和设置在其间的滤纸。 第一盖包括开口。 第二盖覆盖开口并且包括开口上方的孔。 滤纸布置在第一和第二盖子之间的开口上，用于阻止产品通过孔逸出托盘，同时允许水蒸汽通过。 使用用于密封孔的冻干塞子，即使在从室中取出之后，也可以保护容纳产品的托盘免受环境湿度的影响。
-
公开(公告)号：US20100183607A1
公开(公告)日：2010-07-22
申请号：US12730137
申请日：2010-03-23
申请人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： A61K39/395 , C07K16/18 , C07K14/775 , A61K31/573 , A61K38/47 , A61K38/16 , A61K38/48 , A61K31/58 , A61K31/542 , A61K38/44 , A61K31/737 , A61K31/60 , A61K38/49 , A61K31/554 , A61P9/00 , C12Q1/00 , G01N33/00 , C12Q1/28 , G01N33/566 , G01N33/53
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。
-
3.发明申请公开(公告)号：US20060095164A1
公开(公告)日：2006-05-04
申请号：US11301868
申请日：2005-12-12
申请人： Matthew Donnelly , David Chassin , Jeffery Dagle , Michael Kinter-Meyer , David Winiarski , Robert Pratt , Anne Boberly-Bartis
发明人： Matthew Donnelly , David Chassin , Jeffery Dagle , Michael Kinter-Meyer , David Winiarski , Robert Pratt , Anne Boberly-Bartis
IPC分类号： G05D11/00
CPC分类号： H02J3/14 , Y02B70/3225 , Y02B70/3266 , Y04S20/222 , Y04S20/242 , Y10T137/729 , Y10T307/43
摘要： Electrical appliance energy consumption control methods and electrical energy consumption systems are described. In one aspect, an electrical appliance energy consumption control method includes providing an electrical appliance coupled with a power distribution system, receiving electrical energy within the appliance from the power distribution system, consuming the received electrical energy using a plurality of loads of the appliance, monitoring electrical energy of the power distribution system, and adjusting an amount of consumption of the received electrical energy via one of the loads of the appliance from an initial level of consumption to an other level of consumption different than the initial level of consumption responsive to the monitoring.
摘要翻译： 描述了电器能耗控制方法和电能消耗系统。 一方面，一种电器能量消耗控制方法包括提供与配电系统耦合的电器，从配电系统接收设备内的电能，使用该器具的多个负载消耗所接收的电能，监视 配电系统的电能，并且通过器具的一个负载将接收到的电能的消耗量从初始消费水平调整到与响应于监视的初始消耗水平不同的其他消费水平 。
-
公开(公告)号：US08722344B2
公开(公告)日：2014-05-13
申请号：US13683527
申请日：2012-11-21
申请人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： G01N33/53
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。
-
公开(公告)号：US08338110B2
公开(公告)日：2012-12-25
申请号：US12730137
申请日：2010-03-23
申请人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： G01N33/53
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。
-
公开(公告)号：US07781219B2
公开(公告)日：2010-08-24
申请号：US11005563
申请日：2004-12-06
申请人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： G01N33/53
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。
-
公开(公告)号：US20050239136A1
公开(公告)日：2005-10-27
申请号：US11005563
申请日：2004-12-06
申请人： Stanley Hazen , Michael Kinter , Marc Penn , Jonathan Smith , Lemin Zheng
发明人： Stanley Hazen , Michael Kinter , Marc Penn , Jonathan Smith , Lemin Zheng
IPC分类号： A61B20060101 , C07K16/18 , G01N33/53 , G01N33/68 , G01N33/92
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。
-
公开(公告)号：US09278790B2
公开(公告)日：2016-03-08
申请号：US14300346
申请日：2014-06-10
申请人： Derrell Craig McPherson , Christopher L. Hooban , Robert Michael Kinter , Dena H. Kota , Zachary A. Minter
发明人： Derrell Craig McPherson , Christopher L. Hooban , Robert Michael Kinter , Dena H. Kota , Zachary A. Minter
CPC分类号： B65D51/241 , F26B5/06
摘要： A lid assembly is provided for covering and sealing a lyophilizer tray that contains a material for freeze-drying into a product in a lyophilizer chamber. The tray has an opening defined by a peripheral lip. The lid assembly includes a first lid disposable to seal around the lip of the tray, second lid disposed on the first lid, and a filter paper disposed therebetween. The first lid includes an opening. The second lid covers the opening and includes a hole over the opening. The filter paper is disposed over the opening between the first and second lids for inhibiting the product from escaping the tray through the hole while permitting water vapor to pass therethrough. With a lyophilization stopper to seal the hole, the tray containing the product can be protected from environmental humidity even after removal from the chamber.
摘要翻译： 提供盖组件，用于将包含用于冷冻干燥的材料的冻干盘覆盖并密封在冻干室中的产品中。 托盘具有由外围唇缘限定的开口。 盖组件包括一次性用于围绕托盘的唇缘密封的第一盖，设置在第一盖上的第二盖和设置在其间的滤纸。 第一盖包括开口。 第二盖覆盖开口并且包括开口上方的孔。 滤纸布置在第一和第二盖之间的开口上，用于通过孔禁止产品逸出托盘，同时允许水蒸汽通过。 使用用于密封孔的冻干塞子，即使在从室中取出之后，也可以保护容纳产品的托盘免受环境湿度的影响。
-
公开(公告)号：US20130177551A1
公开(公告)日：2013-07-11
申请号：US13683527
申请日：2012-11-21
申请人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： G01N33/92
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
